Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07754474
PHASE1
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity
Sponsor: Boehringer Ingelheim
View on ClinicalTrials.gov
Summary
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related co-morbidity following subcutaneous administration.
Official title: A Phase I, Randomized, Single-blind, Parallel-group Trial for BI 3034701 Compared to Placebo in Participants With Overweight / Obesity
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2026-09-01
Completion Date
2027-01-17
Last Updated
2026-08-10
Healthy Volunteers
No
Conditions
Interventions
DRUG
BI 3034701
BI 3034701
DRUG
Placebo
Placebo
Locations (1)
hVIVO Mannheim
Mannheim, Germany